- Home
- CRWD vs AMGN Comparison
CRWD vs AMGN Comparison
Compare CRWD & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRWD
- AMGN
- Stock Information
- Founded
- CRWD 2011
- AMGN 1980
- Country
- CRWD United States
- AMGN United States
- Employees
- CRWD N/A
- AMGN N/A
- Industry
- CRWD EDP Services
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRWD Technology
- AMGN Health Care
- Exchange
- CRWD Nasdaq
- AMGN Nasdaq
- Market Cap
- CRWD 135.5B
- AMGN 150.8B
- IPO Year
- CRWD 2019
- AMGN N/A
- Fundamental
- Price
- CRWD $501.29
- AMGN $343.30
- Analyst Decision
- CRWD Buy
- AMGN Hold
- Analyst Count
- CRWD 43
- AMGN 14
- Target Price
- CRWD $519.63
- AMGN $313.31
- AVG Volume (30 Days)
- CRWD 2.1M
- AMGN 3.0M
- Earning Date
- CRWD 12-02-2025
- AMGN 11-04-2025
- Dividend Yield
- CRWD N/A
- AMGN 2.76%
- EPS Growth
- CRWD N/A
- AMGN 65.12
- EPS
- CRWD N/A
- AMGN 12.93
- Revenue
- CRWD $4,341,102,000.00
- AMGN $35,971,000,000.00
- Revenue This Year
- CRWD $23.43
- AMGN $8.82
- Revenue Next Year
- CRWD $21.95
- AMGN $1.84
- P/E Ratio
- CRWD N/A
- AMGN $26.64
- Revenue Growth
- CRWD 23.46
- AMGN 10.56
- 52 Week Low
- CRWD $298.00
- AMGN $253.30
- 52 Week High
- CRWD $566.90
- AMGN $345.84
- Technical
- Relative Strength Index (RSI)
- CRWD 43.20
- AMGN 69.85
- Support Level
- CRWD $493.01
- AMGN $331.71
- Resistance Level
- CRWD $539.32
- AMGN $345.49
- Average True Range (ATR)
- CRWD 20.39
- AMGN 7.96
- MACD
- CRWD -5.84
- AMGN 0.13
- Stochastic Oscillator
- CRWD 26.91
- AMGN 94.13
About CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.